DK2783682T3 - Farmaceutisk sammensætning omfattende pimobendan - Google Patents

Farmaceutisk sammensætning omfattende pimobendan Download PDF

Info

Publication number
DK2783682T3
DK2783682T3 DK14171534.2T DK14171534T DK2783682T3 DK 2783682 T3 DK2783682 T3 DK 2783682T3 DK 14171534 T DK14171534 T DK 14171534T DK 2783682 T3 DK2783682 T3 DK 2783682T3
Authority
DK
Denmark
Prior art keywords
pimobendan
pharmaceutical composition
composition comprehensive
comprehensive
pharmaceutical
Prior art date
Application number
DK14171534.2T
Other languages
English (en)
Inventor
Martin Andreas Folger
Jens Lehmann
Stefan Henke
Bernhard Hassel
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34877563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2783682(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Application granted granted Critical
Publication of DK2783682T3 publication Critical patent/DK2783682T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
DK14171534.2T 2004-03-08 2005-03-01 Farmaceutisk sammensætning omfattende pimobendan DK2783682T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004011512.5A DE102004011512B4 (de) 2004-03-08 2004-03-08 Pharmazeutische Zubereitung enthaltend Pimobendan
EP05715625.9A EP1725218B1 (en) 2004-03-08 2005-03-01 Pharmaceutical composition comprising pimobendan

Publications (1)

Publication Number Publication Date
DK2783682T3 true DK2783682T3 (da) 2019-08-12

Family

ID=34877563

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14171534.2T DK2783682T3 (da) 2004-03-08 2005-03-01 Farmaceutisk sammensætning omfattende pimobendan
DK05715625.9T DK1725218T3 (da) 2004-03-08 2005-03-01 Farmaceutisk sammensætning omfattende pimobendan

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05715625.9T DK1725218T3 (da) 2004-03-08 2005-03-01 Farmaceutisk sammensætning omfattende pimobendan

Country Status (25)

Country Link
US (5) US8846679B2 (da)
EP (2) EP2783682B1 (da)
JP (2) JP4757253B2 (da)
KR (2) KR101290077B1 (da)
CN (1) CN100546568C (da)
AR (2) AR047993A1 (da)
AU (1) AU2005218912C1 (da)
BR (1) BRPI0508557B1 (da)
CA (1) CA2557161C (da)
CY (2) CY1115526T1 (da)
DE (1) DE102004011512B4 (da)
DK (2) DK2783682T3 (da)
ES (2) ES2736022T3 (da)
HR (2) HRP20140900T1 (da)
HU (1) HUE045637T2 (da)
IN (1) IN2014DN07624A (da)
LT (1) LT2783682T (da)
MX (1) MXPA06009889A (da)
NZ (1) NZ549630A (da)
PL (2) PL2783682T3 (da)
PT (2) PT1725218E (da)
SI (2) SI1725218T1 (da)
TW (1) TWI355947B (da)
WO (1) WO2005084647A1 (da)
ZA (1) ZA200606154B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP4572296B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP2006028130A (ja) * 2004-07-21 2006-02-02 Toa Eiyo Ltd ピモベンダン経口投与製剤
JP4572293B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
JP4572300B2 (ja) * 2006-01-19 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
WO2010055119A2 (en) * 2008-11-17 2010-05-20 Novartis Ag Pharmaceutical composition comprising pimobendan
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
NL1037569C2 (en) 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
RU2014129508A (ru) 2011-12-21 2016-02-10 Новартис Тиргезундхайт АГ Новая комбинация
WO2013135853A1 (en) * 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical packaging product for the veterinary medical sector
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2013361760B2 (en) * 2012-12-19 2018-07-05 Elanco Animal Health Gmbh Tablets with improved acceptance and good storage stability
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
EP3389638B1 (en) 2015-12-17 2023-08-02 Ceva Santé Animale Pharmaceutical composition comprising pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN106729723A (zh) * 2016-11-21 2017-05-31 青岛农业大学 一种含匹莫苯丹的药物组合物及其制备方法
KR102165805B1 (ko) * 2017-12-22 2020-10-14 주식회사 고려비엔피 기호성이 증진된 개과 동물용 경구 투여 제제
EP4034099A4 (en) * 2019-10-23 2023-10-25 Piedmont Animal Health Inc. Pimobendan formulation and method of use thereof
WO2024126434A1 (en) 2022-12-15 2024-06-20 Boehringer Ingelheim Vetmedica Gmbh Solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
JP7659339B1 (ja) 2023-11-21 2025-04-09 東海カプセル株式会社 ピモベンダンを含有する経口フィルム製剤
WO2026150511A1 (ja) * 2025-01-08 2026-07-16 東海カプセル株式会社 ピモベンダンを含有する経口フィルム製剤

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
JPS5636911A (en) * 1979-09-05 1981-04-10 Aisin Seiki Mechanism for adjusting headrest
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
ZA878182B (en) 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3728244A1 (de) 1987-08-25 1989-03-09 Thomae Gmbh Dr K Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de) 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
IE62095B1 (en) 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
DE4001623A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen geeigneten arzneimittels
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH0570612A (ja) 1991-09-12 1993-03-23 Toyobo Co Ltd 二軸配向ポリエステルフイルム
PT760648E (pt) * 1994-05-20 2002-04-29 Janssen Pharmaceutica Nv Tabletes de flubendazole de mastigacao para animais domesticos
JPH11228302A (ja) 1998-02-18 1999-08-24 Taisho Technos Co Ltd 抗菌防黴組成物
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
PT1260215E (pt) * 2000-03-01 2009-09-03 Eisai R&D Man Co Ltd Comprimido de desintegração rápida que contém poli(álcool vinílico)
EP1311292A2 (en) 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2001225816B2 (en) 2000-12-18 2005-10-13 Novartis Ag Therapeutic combination of amlodipine and benazepril
EP1247456A3 (en) 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
EP1363898A4 (en) 2001-03-02 2004-12-08 Bristol Myers Squibb Co COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE60237696D1 (de) 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
MXPA04010951A (es) 2002-05-23 2005-06-08 Pfizer Nueva combinacion.
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
EP1554267A1 (en) 2002-10-07 2005-07-20 Artesian Therapeutics, Inc. Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity
CA2506741A1 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
AU2003300297A1 (en) 2002-12-23 2004-07-22 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2005281283A (ja) 2004-03-31 2005-10-13 Akira Matsumori ベンズイミダゾール系薬剤の併用医薬
FI20040675A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
NZ534939A (en) 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
US20080090827A1 (en) 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
JP2008521805A (ja) 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
CN1702243A (zh) 2005-05-31 2005-11-30 刘坚雄 无壁板框架结构装配组合式房屋建筑及其建造方法
JPWO2006134877A1 (ja) 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
DK1951227T3 (da) 2005-11-14 2017-07-10 Boehringer Ingelheim Vetmedica Gmbh Anvendelse af pimobendan til behandling af asymptomatisk (okkult) hjertesvigt
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
SI1725218T1 (sl) 2014-09-30
AU2005218912A1 (en) 2005-09-15
AR047993A1 (es) 2006-03-15
MXPA06009889A (es) 2007-11-20
JP2007526269A (ja) 2007-09-13
CN1929821A (zh) 2007-03-14
PT2783682T (pt) 2019-09-10
HRP20191360T1 (hr) 2019-11-01
AU2005218912C1 (en) 2012-10-25
KR101290077B1 (ko) 2013-08-01
JP5875231B2 (ja) 2016-03-02
PL2783682T3 (pl) 2019-11-29
US20120148640A1 (en) 2012-06-14
BRPI0508557A (pt) 2007-08-07
TW200539901A (en) 2005-12-16
EP2783682B1 (en) 2019-05-22
IN2014DN07624A (da) 2015-07-10
KR20120006089A (ko) 2012-01-17
AR106850A2 (es) 2018-02-21
US8846680B2 (en) 2014-09-30
DE102004011512B4 (de) 2022-01-13
EP1725218B1 (en) 2014-06-25
US20170368062A1 (en) 2017-12-28
SI2783682T1 (sl) 2019-08-30
NZ549630A (en) 2009-07-31
US20130177613A1 (en) 2013-07-11
US20050203097A1 (en) 2005-09-15
LT2783682T (lt) 2019-07-25
ES2736022T3 (es) 2019-12-23
PL1725218T3 (pl) 2014-11-28
WO2005084647A1 (en) 2005-09-15
US8859554B2 (en) 2014-10-14
TWI355947B (en) 2012-01-11
EP1725218A1 (en) 2006-11-29
JP2011098977A (ja) 2011-05-19
JP4757253B2 (ja) 2011-08-24
PT1725218E (pt) 2014-09-03
CA2557161C (en) 2013-06-25
ZA200606154B (en) 2007-11-28
DK1725218T3 (da) 2014-09-01
EP2783682A1 (en) 2014-10-01
DE102004011512A1 (de) 2005-09-22
US20140363510A1 (en) 2014-12-11
CN100546568C (zh) 2009-10-07
KR20070014143A (ko) 2007-01-31
CY1121877T1 (el) 2020-10-14
CY1115526T1 (el) 2017-01-04
AU2005218912B2 (en) 2010-09-16
ES2501216T3 (es) 2014-10-01
HUE045637T2 (hu) 2020-01-28
US8846679B2 (en) 2014-09-30
HRP20140900T1 (hr) 2014-11-07
BRPI0508557B1 (pt) 2018-12-18
CA2557161A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
BRPI0511900A (pt) composições farmacêuticas
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0613033A2 (pt) composição oral
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
NO20055686D0 (no) Sammensetning
MA28801B1 (fr) Composition antihistaminique
DE602005020716D1 (de) Fluoroelastomere
DK1957073T3 (da) Lægemiddel
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
FR2871686B1 (fr) Composition anti-decoloration
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
BRPI0614413A2 (pt) composto, e, composição farmacêutica
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
NO20042027D0 (no) Oral composition
DK1753431T3 (da) Farmaceutisk sammensætning omfattende ZD6474
SE0400205D0 (sv) Composition